Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Charles Peterfy, Xin Ye, Heather Gelhorn, Rebecca M Speck, Peter J. Countryman, Vicki Leigh Keedy, Zev A. Wainberg, Arun S. Singh, Bartosz Chmielowski, Daniel D. Von Hoff, Hani M. Babiker, Vivek Khemka, Gregory Michael Cote, Geoffrey Shapiro, Andrew J. Wagner, John H. Healey, Henry Hsu, Paul S. Lin, Sandra Tong, William D. Tap
Institutions: Vanderbilt University Medical Center, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Los Angeles Medical Center, Translational Genomics Research Institute, HonorHealth, University of Arizona Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Plexxikon (United States)
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889828602